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Hemangiomas represent the most common tumor of 
infancy with the highest incidence in preterm infants 
(1). They are usually not present at birth but develop 
in the first few weeks of life and proliferate in the 
following weeks and months. The etiology is not yet 
fully understood but vascular endothelial growth factor 
(VEGF) may play an important role. Multiple heman­
giomas are defined by five or more heman giomas, are 
usually smaller in size and more likely to be associated 
with visceral hemangiomas (2).
INTRODUCTION
3
CASE REPORT
4
We present a male preterm infant born to a healthy 
31­year­old G1/P1 by Cesarean section at 28 4 /7 weeks 
due to preeclampsia.
The baby had a birthweight of 1100 g (P 25 – 50). Apgar 
scores were 6, 8 and 8 at 1, 5 and 10 minutes, respec­
tively, and the arterial umbilical cord pH was 7.27. He 
was transferred to the neonatal intensive care unit with 
mild respiratory distress on nasal CPAP and required a 
maximal FiO2 of 0.3. His postnatal course – apart from 
an episode of late­onset sepsis – was un remarkable. 
At about 3 weeks of age, a few tiny hemangiomas 
the size of a pinhead were noted (Fig. 1 – 2). Over the 
next few weeks, the number and size of the hemangi­
omas increased. Abdominal ultrasound did not reveal 
any intestinal or liver hemangiomas. As the cuta neous 
hemangiomas were small and not located close to 
orifices, specific therapeutic interventions were not 
deemed necessary.
At the corrected age of 3 months, the baby was 
discharged home. At that time, there were a total 
of 83 hemangiomas, some of them having shown an 
impressive increase in size (Fig. 3 – 4).
Fig. 1
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At the age of 3 weeks, several small hemangiomas 
were noted (back).
Fig. 2
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At the age of 3 weeks, several small hemangiomas 
were noted (chest).
Fig. 3
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Multiple hemangiomas at a corrected age of  
3 months (back). 
Fig. 4
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Multiple hemangiomas at a corrected age of 3 
months (chest and axilla).
9DISCUSSIONThis case report of a premature infant with multiple 
cutaneous hemangiomas without visceral involve­
ment illustrates a common problem in this population. 
About 25% of preterm infants develop hemangiomas 
during the neonatal period compared to around 5% 
of term infants (3). Infantile hemangiomas are clas­
sified as focal or localized, segmental, indeterminate 
and multifocal infantile hemangiomas (4). Multiple 
hemangiomas are mainly located on the skin, but 
these infants have a higher risk of internal heman­
giomas, which are particularly located in the liver. 
Ulceration and bleeding are the typical complications 
of cutaneous hemangiomas. These infants require 
regular clinical and sonographic follow­up including 
precise documentation of the lesions (5).
Infantile hemangiomas are vascular tumors. Initially, 
there is a proliferating phase in the first six to nine 
months of age, followed by an involution phase over 
years which ultimately leads to a residual, mostly fibro­
tic mass. The differential diagnosis includes other vas­
cular tumors, as well as other vascular malfor mations, 
which in contrast to infantile hemangiomas are usually 
present at birth. 
The exact pathogenesis of multiple infantile hemangi­
omas is not yet fully understood. There are different 
hypotheses, however, vascular endothelial growth fac­
tor A (VEGF­A), an important molecule in angiogenesis 
and vasculogenesis, likely plays a role. In addition, cell 
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embolization from the placenta, somatic mutations in 
a gene mediating endothelial cell proliferation, endo­
thelial progenitor cell and hypoxia have all been impli­
cated (6 – 9).
According to the European Propranolol In the Treat­
ment of Complicated Haemangiomas (PITCH) study, 
there are three main indications for treatment: 
1) periocular location with threat to vision, 2) location 
on the face with risk of cosmetic disfigurement and 
3) risk for ulceration and bleeding, seen for example 
in perianal hemangiomas (10). Overall, treatment is 
rarely required and long­term outcome is good.
Therapeutic options include systemic or local treat­
ment with beta blockers, cryotherapy, or laser coa­
gulation. Since beta blocker treatment has become 
available, surgery is now only rarely required. Cortico­
steroids are generally not used in infantile hemangio­
mas. Modifying VEGF­A action could be a promising 
therapeutic option in the future, but, at this point, 
results of randomised controlled trials are still lacking. 
Propranolol therapy for infantile hemangiomas was 
used in 2008 for the first time and since then has 
rapidly become the first line treatment. Its effect on 
infantile hemangiomas was discovered by chance: 
Léauté­Labrèze et al. used corticosteroids to treat a 
patient with a nasal hemangioma. During this treat­
ment, the hemangioma stabilized in size but the 
11
patient developed hypertrophic obstructive cardiomy­
opathy, which in turn was treated with propranolol. 
The treatment team observed rapid involution of the 
hemangioma (11).
Oral propranolol therapy should be started with a 
dose of 1 mg/kg/day in the hospital setting to monitor 
heart rate, blood pressure and glucose concentrations. 
If well tolerated, it can be increased to maintenance 
dose of 2 mg/kg/day (12). The main side effects are 
mild and include sleep disturbance and cool extre­
mities. At higher doses, fatigue and bradycardia can 
occur. Treatment response depends on timing and 
duration of treatment. There is no consensus regar­
ding the optimum treatment duration, but studies 
suggest that the risk for rebound growth decreases 
after 12 months (12). Rebound growth has been 
reported to occur in up to 20% of patients. Risk factors 
for rebound growth are short duration of propranolol 
therapy, female gender, deep infantile hemangiomas 
and abrupt discontinuation of therapy (13).
In summary, infantile hemangiomas are very common 
in premature infants. Usually, they are not present 
at birth but proliferate in the first few months with 
a peak around the age of 3 – 6 months, followed by 
a stable phase for another 2 years and a regression 
phase until the age of 4 – 5 years. The pathogenesis 
of infantile hemangioma is still not fully understood. 
Whether active treatment is required depends on 
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localization and size of the lesions as well as the risk 
for complications. Overall, only a small proportion of 
patients needs therapy. Local or systemic propranolol 
is the first line treatment. It is safe and highly effec­
tive, but compliance is important and parents should 
be informed about the potential and usually mild side 
effects.
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